UpdatesPlus-Nicotinic Receptors (February 2008)
The February edition of UpdatesPlus-Nicotinic Receptors has now been published.
Providing a detailed view and analysis of all key information from the exciting and rapidly expanding field of neuronal nicotinic receptors, this service is a must to all involved in CNS drug development.
UpdatesPlus is available as a yearly subscription.
Subscribe now and receive the next 12 monthly editions plus our recent report:
What's in the February 2008 edition of UpdatesPlus-Nicotinic Receptors?
The February 2008 edition of UpdatesPlus-Nicotinic Receptors reports on key events identified through tracking of:
- Journal Publications
- Clinical Trials
- Company Press Releases
- Investor presentations
This month, as usual we provide a fully up to date snapshot of the nicotinic receptor ligand pipeline. In addition we report on breaking activity:
-
SSR-180711entry into phase 2 development. We provide analysis on the study design and how this may place Sanofi-Aventis in a position of strength
- New research evaluating the competitive relationship between cannabinoid and nicotinic receptor ligands and how stakeholders could benefit or lose through this relationship
- A full analysis of recent activity around Chantix/Champix including analysis of the implications of approval in Japan; emerging safety issues relating to psychiatric risk
- Sanofi-Aventis' decision to drop dianicline
- The potential to treat post-traumatic stress disorder (PTSD) wih nicotinic receptor ligands. We provide an analysis of the potential market for this indication as well as advantages over existing SSRI treatments
- New pipeline activity within Servier
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
About UpdatesPlus: Through DailyUpdates, LeadDiscovery has access to one of the most comprehensive sources of information for the drug development sector. UpdatesPlus takes this information and uses our industrial experience to provide a monthly analysis of breaking activity in selected indications and molecular targets. If this is the first time that you have heard of UpdatesPlus please take a moment to have a look at an example. If you would find such a service of use in your area contact us now.
Other users found this report page using the following search terms: nicotinic alzheimer's cias schizophrenia schizoaffective nicotinic receptors updatesplus powerpoint nicotinic ligand
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.